Oseltamivir Use During Breastfeeding

Primary Recommendation

• The American Academy of Pediatrics recommends oseltamivir as the preferred antiviral agent for breastfeeding mothers with influenza, and breastfeeding should not be discontinued 1
• The American Academy of Pediatrics explicitly states that none of the antiviral agents, including oseltamivir, are reasons to discontinue breastfeeding 1

Dosing for Breastfeeding Mothers

• Breastfeeding mothers with influenza should receive oseltamivir 75 mg twice daily for 5 days and continue breastfeeding without interruption 1, 2, 3
• Treatment should be initiated within 48 hours of symptom onset for maximum benefit, though later initiation can still provide clinical benefit 4

Breastfeeding Management During Maternal Influenza

• Direct breastfeeding should be encouraged even when the mother has confirmed influenza 3
• Breastfeeding provides protective benefits against influenza through activation of innate antiviral mechanisms, specifically type 1 interferons 3
• Breast milk from mothers vaccinated during the third trimester contains higher levels of influenza-specific immunoglobulin A 3

Critical Clinical Considerations

• Do not delay treatment while waiting to determine breastfeeding status—the benefits of treating maternal influenza outweigh any theoretical risks to the nursing infant 1
• Oseltamivir is FDA-approved for infants as young as 2 weeks of age for treatment, further supporting its safety profile in the breastfeeding context 1, 2

Common Pitfalls to Avoid

• Never advise discontinuation of breastfeeding due to maternal oseltamivir use—this is explicitly contraindicated by AAP guidelines 1
• Do not withhold oseltamivir treatment from breastfeeding mothers due to concerns about infant exposure through breast milk 1, 3